COPD, COVID-19
Conditions
Brief summary
The purpose of the study is to determine the difference between The Breather respiratory muscle trainer and pulmonary rehabilitation in patients with COPD post COVID-19.
Detailed description
The main concern in post COVID-19 patients is the involvement of respiratory system and cardiovascular system which may result in dyspnea, low blood oxygen saturation, and decrease cardiopulmonary efficiency. In cases of post COVID-19 patients with COPD their state is deconditioned and more critical than normal to be either in the zone of progression or regression or stability as the studies showed that handling of these cases during (3-6 months post-COVID) will prevent these symptoms from becoming permanent.
Interventions
OTHERThe breather respiratory muscle trainer
The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
OTHERDiaphragmatic and localized breathing exercises
A. Diaphragmatic breathing exercises: Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day. B. Localized Breathing: Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day. C. Mild Interval training exercise
OTHERinterval aerobic training and respiratory training
mild intensity interval aerobic training and respiratory training on treadmill
Sponsors
Horus University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. SPO2 ≥ 93% 2. Their age ranges from 30-40 years old. 3. COPD patients GOLD1 (Mild FEV1≥80% predicted) and GOLD2 (Moderate 50% ≤FEV1\<80%predicted) (Manian, 2019) 4. patients diagnosed as post COVID-19 Pneumonia between 3 and 6 Months ago with CT scan and PCR testing. 5. Their body mass index (BMI) ranged from 20 to 29.9kg/m2. 6. Stable medical cases with dyspnea
Exclusion criteria
Patients who will meet one of the following criteria will be excluded from the study: 1. patients with cardiac problems e.g. atrial fibrillation, left bundle-branch block, heart failure. 2. Sever cases of COPD (FEV1/FVC\< 50%) 3. Mitral or aortic valvular disease, pericardial effusion. 4. Recent myocardial infarction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of change in Forced expiratory volume in the first one second expressed as percentage of the predicted FEV1 | at baseline and 3 months of intervention | To assess the change in the Forced expiratory volume in the first one second expressed as a percentage of the predicted FEV1 (FEV1%) by spirometry. The unit of measure is the liters. |
| Assessment of change in Physical Fitness Index (PFI) | at baseline and 3 months of intervention | To assess the change in Physical Fitness Index (PFI) By using Modified Harvard Step Test (HST): The test will be done on a step height of 33 cm height. PFI was calculated by using following formula |
| Assessment of change in Rate Pressure Product | at baseline and 3 months of intervention | To assess the change in Rate Pressure Product. First, the baseline heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be recorded, by an aneroid sphygmomanometer. HR will be constantly displayed on pulse oximetry. The rate-pressure product (RPP) = HR X SBP |
| Assessment of change in Forced vital capacity | at baseline and 3 months of intervention | To assess the change in Forced vital capacity (FVC) by spirometry. The unit of measure is liters. |
| Assessment of change in Forced expiratory volume in the first one second | at baseline and 3 months of intervention | To assess the change in Forced expiratory volume in the first one second (FEV1) by spirometry. The unit of measure is liters. |
| Assessment of change in Ratio of forced expiratory volume in the first one second to the forced vital capacity of lungs | at baseline and 3 months of intervention | To assess the change in the ratio of forced expiratory volume in the first one second to the forced vital capacity of lungs (FEV1/FVC) by spirometry. The unit of measure is the ratio. |
| Assessment of change in Maximum voluntry ventilation | at baseline and 3 months of intervention | To assess the change in the maximum voluntary ventilation (MVV) by spirometry. The unit of measure is the liters/ minute. |
| Assessment of change in Forced vital capacity expressed as percentage of the predicted FVC | at baseline and 3 months of intervention | To assess the change in the Forced vital capacity expressed as a percentage of the predicted FVC (FVC%) by spirometry. The unit of measure is the liters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of change in Oxygen saturation | at baseline and 3 months of intervention | To assess the change in the Oxygen saturation using pulse oximeter device. |
Countries
Egypt
Contacts
Primary ContactEman Rashad, Assistant lecturer
Outcome results
None listed